Cambridge, UK – Cresset, innovative provider of computational solutions and services for small molecule drug discovery and design, is pleased to announce the appointment of David Newble as Non-Executive Director. “I’m delighted to welcome David to the Cresset Board to advise and contribute to the continued growth of the company,” says Dr Robert Scoffin, CEO, […]
Orion™ Molecular Design Platform Helps Pharmaceutical, Biotechnology Companies Better Identify, Optimize, and Order Hits and Leads from Mcule’s database SANTA FE, N.M., & PALO ALTO, Calif. – OpenEye Scientific and Mcule – a leading online marketplace for drug discovery – today announced that OpenEye’s Orion™ molecular design platform now can greatly enhance the ability to […]
CAMBRIDGE, UK: Optibrium™, a developer of software for drug discovery, today announced the appointment of Dr Rae Lawrence as Director of Software Development. With the continued success of the Company’s portfolio of cheminformatics and AI-based drug discovery software, and the recent backing by Kester Capital, Optibrium has made the new appointment to drive its product development […]
Investment by Kester Capital will drive commercial growth and the development of new products to improve speed, efficiency, and productivity of the discovery process CAMBRIDGE, UK: Optibrium™, a developer of software for drug discovery, today announced it has raised significant investment from Kester Capital, a leading UK mid-market private equity firm typically investing between £10 to […]
Sygnature Accelerates Customers’ Drug Discovery Timelines with Improved Hit Identification, Lead Optimization Capabilities SANTA FE, N.M., USA, & NOTTINGHAM, UK – 21 January 2021 – OpenEye Scientific and Sygnature Discovery – a world-leading integrated discovery and pre-clinical solutions provider – today announced the adoption of OpenEye’s Orion™ platform to power Sygnature’s computational efforts in molecular design drug […]
DeepMatter Group plc, the AIM-quoted company focusing on digitising chemistry, is pleased to announce that one of its wholly owned subsidiaries has entered into a multi-year, limited-use data licensing agreement with the Life Science business of Merck to provide proprietary chemical structure and reaction data content to Merck’s selected application. Merck, a leading science and […]
New features include reaction-based library enumeration for novel molecule generation and optimisation AI-integrated with seamless interface to Optibrium’s Artificial Intelligence platform, Cerella, to extract greater value from drug discovery data CAMBRIDGE, UK: Optibrium™, a developer of software for drug discovery, today announced the release of the newest version of StarDrop™, a comprehensive software platform for small […]
DeepMatter Group plc, the AIM-quoted company focusing on digitising chemistry, is pleased to announce that it has signed a three-year contract with Thieme Chemistry, which is part of the Thieme Group, an award-winning international medical and science publisher serving health professionals and students for more than 130 years, for the supply of technical data services […]
Optibrium, Intellegens and Medicines Discovery Catapult combine their expertise in drug discovery and AI research CAMBRIDGE, and MACCLESFIELD, UK – The consortium behind the DeepADMET project set up to advance artificial intelligence (AI) technologies for drug discovery, today announced the successful conclusion of this project which was funded by Innovate UK, the UK’s innovation agency. Optibrium […]
PRINCETON, NJ. – Certara, Inc. (“Certara”) today announced the launch of its initial public offering of 24,390,000 million shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission. Certara is offering 14,630,000 shares of common stock and certain selling stockholders are offering 9,760,000 shares of common stock in […]
Pay Invoice
Latest Blogs
-
Lab Instrument Sales in China Collapse
March 29, 2024 1:15 pm
-
Pittcon 2024 Comes to San Diego
February 14, 2024 1:10 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
